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ABSTRACT 
The immune system has most likely evolved to limit the negative impact exerted by 
pathogens on host homeostasis. This defense strategy relies on the concerted action of 
innate and adaptive components of the immune system, which sense and target pathogens 
for containment, destruction or expulsion. Resistance to infection refers to these immune 
functions, which reduce the pathogen load of an infected host as the means to preserve 
homeostasis. Immune-driven resistance to infection is coupled to an additional, and arguably 
as important, defense strategy that limits the extent of dysfunction imposed to host 
parenchyma tissues during infection, without exerting a direct negative impact on pathogens. 
This defense strategy, called disease tolerance, relies on tissue damage control 
mechanisms that prevent the deleterious effects of pathogens, while uncoupling immune-
driven resistance mechanisms from immunopathology and disease. Here we provide a 
unifying view of resistance and disease tolerance within the framework of immunity to 
infection. 
 
INTRODUCTION 
The pathological outcome of infection is largely determined by the degree of metabolic 
dysfunction and damage inflicted upon the host’s parenchyma tissues1, 2. Clinical signs and 
symptoms of infectious diseases emerge as host homeostasis [G] becomes compromised 
due to tissue dysfunction and damage1-3. Current understanding of this pathological process 
is limited, presumably impairing the ability to treat infectious diseases that remain associated 
with high human morbidity and mortality4. 
Immunity provides protection against disease, in general, and particularly against 
infectious diseases4. This is achieved by virtue of immune-driven resistance mechanisms 
that expel, contain, or kill pathogens as the means to preserve host homeostasis. 
Therapeutic approaches based on the induction of such immune-driven resistance 
mechanisms, such as vaccination, have proven highly protective against a broad range of 
infectious diseases4. This is also the case for anti-microbial agents, like antibiotics, that 
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functionally mimic resistance mechanisms containing or killing pathogens4. The 
overwhelming success of these therapeutic approaches has likely contributed to the 
perception that resistance mechanisms are the only relevant defense strategy against 
infectious diseases. This notion has been challenged over the past years by the 
(re)discovery of disease tolerance5, 6. This evolutionarily conserved host defense strategy, 
which was first described in plants7, 8, is fully operational in flies9, 10 and mammals, including 
rodents11, 12 and humans13, where it preserves host homeostasis in response to viral14, 15, 
bacterial15-18, fungal19 and protozoan11, 13, 20, 21 infections. In contrast to resistance to infection, 
disease tolerance does not exert a direct negative effect on these pathogens6.  
Revealed through the recognition that variation in disease severity can occur at a 
population level without a direct correlation to pathogen load, disease tolerance is now 
widely studied mechanistically, using experimental models of infection in which the 
relationship between host health and pathogen load can be established at an individual level 
(Box 2). Here we review the cellular and molecular mechanisms conferring disease 
tolerance to infection and explore the impact exerted by bona fide immunity on those 
mechanisms. We also bring to light how the establishment of symbiotic interactions with 
microbes and their regulation by specific components of innate and adaptive immunity 
impact on disease tolerance to infection (see also22). Finally, we put forward that the 
mechanisms underlying disease tolerance to infection can be targeted therapeutically 
against infectious diseases. 
 
TISSUE DAMAGE CONTROL 
The mechanisms underlying disease tolerance remain poorly understood, but appear to 
revolve around a number of evolutionarily conserved stress and damage responses 
conferring tissue damage control in the infected host1-3 (Figure 1). These stress and damage 
responses sustain the functional outputs of host parenchyma cells under different forms of 
stress and damage imposed either directly by pathogens, i.e. virulence, or indirectly by host 
immune-driven resistance mechanisms, i.e. immunopathology1, 3 [G]. Stress and damage 
responses provide metabolic adaptation while repairing damage to cellular metabolites, 
macromolecules and/or organelles, as the means to preserve core cellular functions, often to 
the detriment of accessory ones1, 3. When these responses fail per se to sustain the 
functional outputs of parenchyma tissues the default program becomes programmed cell 
death (Figure 1). This is coupled to the induction of cellular and tissue regenerative 
responses that restore the functional output of damaged parenchyma tissues3, 23. As 
discussed in further detail below, different types of infection impose distinct forms of stress 
and damage to host parenchyma cells, suggesting that tissue damage control mechanisms 
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might act in a somewhat pathogen class-specific manner that reflects these differences such 
as to effectively establish disease tolerance against diverse types of infection6. While there 
are clearly parallels between the protective effect exerted by tissue damage control 
mechanisms in the context of infectious and non-infectious diseases1, 6, 24, we shall restrict 
our discussion here to infectious diseases.  
 
STRESS RESPONSES IN TISSUE DAMAGE CONTROL 
Stress responses are triggered through the engagement of specific sensors that 
continuously monitor different physiological parameters under homeostatic regulation such 
as temperature, O2, pH, osmolarity, glucose and ATP1-3. When these parameters change 
beyond a certain threshold, “stress sensors” set off signal transduction pathways that alert 
cells for a possible disruption of homeostasis1-3. The ensuing stress responses provide 
metabolic adaptation in host cells, conferring tissue damage control and disease tolerance to 
infection1-3 (Figure 1&2). While recognition of pathogens via pattern recognition receptor 
(PRR) can contribute to tissue damage control and to the establishment of disease 
tolerance25, we shall not address it in further detail herein as this has been covered in detail 
elsewhere24, 26. Instead we shall highlight a number of bona fide stress responses involved in 
tissue damage control mechanisms that contribute to the establishment of disease tolerance 
to infection1-3. 
Oxidative stress. The oxidative stress response orchestrated by the transcription factor, 
nuclear factor E2-related factor-2 (NRF2)27, 28 (Figure 2) can contribute critically to the 
establishment of disease tolerance to infection, as demonstrated for malaria20, 29. Briefly, the 
blood stage of Plasmodium infection is associated with hemolysis and hence with generation 
of extracellular hemoglobin20, 21, 29, 30. Upon oxidation, extracellular hemoglobin releases its 
prosthetic heme groups, which act as catalysts in the production of reactive oxygen species 
(ROS) and nitrogen species (RNS). This can lead to oxidative stress and cellular damage in 
host parenchyma tissues12, 13, 16, 31, driving the pathogenesis of severe forms of malaria30. 
Sickle hemoglobin, a genetic polymorphism in the β chain hemoglobin gene naturally 
selected through human evolution, confers disease tolerance to malaria20, 32, via a 
mechanism that counters the pathogenic effects of labile heme via the activation of NRF220, 
30, 33. While NRF2 is also protective against polymicrobial34 and Staphylococcus aureus35 
infections, it is not clear whether this is due to the establishment of disease tolerance but the 
two following observations suggest that it is so: i) NRF2 polarizes macrophage responses 
towards the promotion of tissue damage control and disease tolerance36, 37, and ii) NRF2 
induces mitochondrial biogenesis in parenchyma cells35, which is likely to contribute to tissue 
damage control and disease tolerance to infections. 
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Hypoxia. Infections can be associated with local or systemic decrease in O2 supply to host 
cells, a condition known as hypoxia. This is sensed and countered by host cells via a stress 
response controlled by the hypoxia inducible factor (HIF) family of transcription factors38 
(Figure 2). Whether HIF activation in parenchyma cells contributes to the establishment of 
disease tolerance to infection has not been established, but HIF activation in macrophages, 
which shifts ATP production via anaerobic glycolytic metabolism, modulates macrophage 
polarization39, 40 towards an effector response that promotes tissue damage control and 
disease tolerance to infection, as illustrated for Helicobacter pylori infection in mice41.  
Metabolic stress. Stress sensors monitor variations in the relative concentration of essential 
metabolites such as for example ATP and glucose1, 3. These variations activate stress 
responses that adjust host cellular metabolism to the relative availability of the metabolites 
sensed. Presumably metabolic stress responses confer tissue damage control and 
contribute to the establishment of disease tolerance to different types of infection (Figure 2). 
In strong support of this notion is the recent finding that stress responses that adjust host 
glucose metabolism confer tissue damage control and establish disease tolerance to viral 
and bacterial infections in mice42.  
Osmotic stress. Osmotic stress, associated with systemic infections43, is sensed and 
regulated by the infected host, via several mechanisms including the activation of nuclear 
factor of activated T cells 5 (NFAT5)44	(Figure 2). The osmotic stress response regulated by 
this transcription factor acts in a cytoprotective manner in parenchyma cells45, conferring 
tissue damage control in the kidney during systemic polymicrobial infections46	and likely in 
the heart during infection with coxsackievirus47 in mice (Figure 2).  
 
DAMAGE RESPONSES AND TISSUE DAMAGE CONTROL 
When stress associated with infection persists in strength and/or time, metabolic adaptation 
is no longer sufficient per se to preserve core cellular functions in parenchyma tissues and 
organs sustaining homeostasis. The ensuing damage inflicted to cellular metabolites, 
macromolecules, i.e. DNA, proteins and lipids, and organelles, activates specific damage 
responses that contribute to tissue damage control and to the establishment of disease 
tolerance to infection1-3 (Figure 1&2). 
Metabolite damage and extracellular release. Metabolite damage refers to modifications 
of metabolites that compromise their original function48, exerting pathologic effects, namely: 
i) impairing host cellular functions and ii) generating “toxic” products that catalyze 
inflammation, cellular stress and damage48. For example, modifications of soluble 
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metabolites that promote phase transition into crystals, are sensed by PRR and trigger 
inflammatory responses that are deleterious to the host49. It follows that limiting the pro-
inflammatory effects of metabolite damage can promote disease tolerance to infection 
(Figure 2). 
Lipid damage. Lipid peroxidation can impair cellular membrane function, eventually leading 
to release of intracellular content50	 (Figure 2). Moreover, sensing of lipid peroxidation 
products by the PRR Toll-like receptor 4 (TLR4), tissue damage, as demonstrated in the 
pathogenesis of Influenza virus infection51. Inhibition of lipid peroxidation by peroxidase 4 
(GPX4)28, 52, relies on glutathione supply by a NRF2-regulated pathway involving, SLC7A11, 
which together with SLC3A2 encode the cystine/glutamate antiporter, GCLC and GCLM that 
encode the γ-glutamylcysteine synthetase (γGCS) and GSS that encodes the glutathione 
synthetase28, 52. Activation of the transcription factor NRF2 also counters lipid peroxidation 
via the expression of heme oxygenase-1 (HO-1)31	(Figure 2).  
Proteoxic damage. Proteotoxic damage responses are aimed at repairing or eventually 
degrading unfolded nascent or mature proteins as a means to preserve essential cellular 
functions53, 54. Proteotoxic damage responses can act as bona fide tissue damage control 
mechanisms, promoting the establishment of disease tolerance to bacterial infection53, 55-58	
(Figure 2). Of note, proteotoxic damage responses are also involved in the regulation of 
immune-driven resistance mechanisms against intracellular bacteria and viruses, some of 
which evolved to modulate these responses as a strategy to repress host resistance to 
infection53	59.	
DNA damage. Infections are associated with DNA damage and the activation of  DNA 
damage responses60 (Figure 2). This occurs most likely via a mechanism involving the 
Mre11/Rad50/Nbs1 complex, which activates for example ataxia-telangiectasia mutated 
(ATM) kinase, a master regulator of the double-stranded DNA damage response61. 
Activation of ATM confers tissue damage control and disease tolerance to polymicrobial 
infections in mice17, suggesting that DNA damage responses contribute to maintain both the 
genetic integrity and the functional outputs of parenchyma cells during infection. 
Damage to cellular organelles. Autophagy is an evolutionary conserved damage response 
that supports cell function under stress conditions that elicit damage to cellular organelles 
(Figure 2)	62. Autophagy regulates inflammatory responses and modulates disease tolerance 
to infections such as Sindbis virus63, S. aureus64 and polymicrobial17 infections in mice. Of 
note, autophagy can act as a resistance mechanism against intracellular pathogens, i.e. 
xenophagy62. 
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PROGRAMMED CELL DEATH IN TISSUE DAMAGE CONTROL 
When stress and damage responses fail to preserve cellular functional outputs, the default 
response is, in most cases, programmed cell death (Figure 1). Different forms of stress and 
damage are associated with distinctive forms of programmed cell death and ensuing 
pathophysiological consequences65. For example, failure to resolve oxidative stress can lead 
necroptosis [G]66 while failure to repair lipid peroxidation induces ferroptosis [G]67.	
Irreparable DNA damage results in the induction of different programmed cell death 
pathways, including apoptosis68, regulated by the caspase family of cysteine proteases. 
While programmed cell death can damage host parenchyma tissues and lead to organ 
dysfunction, this relationship is not always straightforward because programmed cell death is 
also part of a resistance mechanism against intracellular pathogens69. However, the trade-off 
of this resistance mechanism can be particularly high, depending on the relative capacity of 
different tissues to withstand cell loss without compromising tissue function and 
homeostasis6. The pathophysiological relevance of this defense strategy is supported by the 
number of mechanisms deployed by intracellular pathogens to promote or inhibit host 
genetic programs controlling programmed cell death, presumably as a strategy to escape 
resistance to infection70. 
Programmed cell death of infected cells is coupled to their immediate phagocytosis by 
bystander macrophages. Dendritic cells (DCs) also take up dying infected cells, processing 
and presenting pathogen-associated antigens to CD4+ T helper (TH) or CD8+ cytotoxic T 
lymphocytes (CTLs) and eliciting antigen-specific adaptive immune responses that target 
and kill the remaining reservoir of infected cells. 
Clearance of damaged and dying cells is associated with macrophage polarization 
towards the production of cytokines and pro-resolving lipid mediators71 including IL-10 and 
15-Deoxy-Δ-prostaglandin J2 (15d-PGJ2), respectively, which induce the expression HO-172, 
73. This macrophage response is also associated with the production of growth factors, such 
as platelet-derived growth factor (PDGF) and cytokines, such as transforming growth factor-
β1 (TGFβ1), which can act directly on parenchyma cells to promote tissue regeneration, 
orchestrating yet another layer of tissue damage control23.  
While some tissue damage control mechanisms act in cell-autonomous manner, others 
appear more to rely on bystander innate and adaptive immune cells. As discussed in the 
next section, tissue resident leukocytes play a predominant role in this non-cell autonomous 
establishment of disease tolerance to infection. 
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IMMUNE REGULATION OF TISSUE DAMAGE CONTROL 
In this section we illustrate how tissue-resident macrophages, innate lymphoid cells (ILCs) 
and regulatory T (TREG) cells impact on tissue damage control mechanisms, and thereby 
contribute in a non cell-autonomous manner to the establishment of disease tolerance to 
infection (Figure 3). 
Macrophages. Tissue resident macrophages express high levels of PRR and a variety of 
other receptors that sense pathogen associated molecular patterns (PAMP), damage 
associated molecular patterns (DAMP) and other alarmins [G] including cytokines released 
from damaged cells, which alert for disruption of homeostasis74, 75 (Figure 3a). These 
cytokines include IL-1α, IL-18 and IL-33, which polarize macrophages towards tissue healing 
regenerative responses, and as discussed in the previous section, contribute to the 
establishment of disease tolerance to infection	 (Figure 3a). Signaling via the aryl 
hydrocarbon receptor (AhR) a ligand-dependent transcription factor that senses exogenous 
environmental toxins and endogenous ligands, can also polarize macrophages towards the 
establishment of disease tolerance to bacterial infections18. 
Macrophage anti-microbial responses are also associated with the expression of genes 
that can promote tissue damage control in parenchyma cells, for example, inducible nitric 
oxide synthase (NOS2), HO-1 and cystathionine β-synthase (CBS), which generate nitric 
oxide (NO), CO and hydrogen sulfide (H2S), respectively (Figure 3a). These 
gasotransmitters76 can diffuse across cellular membranes and drive metabolic adaptation in 
microbes77 as well as in parenchyma cells76, 78, supporting tissue damage control and 
disease tolerance to infection (Figure 3a). Cytokines produced during these responses exert 
a dual role, for example, tumor necrosis factor (TNF) can trigger programmed cell death 
while also activating pro-survival responses via activation of the nuclear factor kappa B (NF-
κB) family of transcription factors79 (Figure 3a). 
Phagocytosis is also associated with the production of ROS by macrophages, supporting 
stem cell division and differentiation towards tissue healing and regeneration80. The 
mechanism via which this occurs involves the repression Nrf281, revealing a tight integration 
of stress and damage responses with subsequent tissue repair and regeneration programs 
restoring host homeostasis23, 80, 82 (Figure 1, 2). How these apparently conflicting activities 
exerted by cytokines such as TNF or ROS are resolved remains to be understood23. This 
suggests nevertheless, that anti-microbial macrophage responses have built-in feedback 
loops promoting tissue damage control. 
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Innate lymphoid cells. All three classes of ILCs, i.e. ILC1, ILC2 and ILC3, play a critical role 
in sensing tissue dysfunction and damage, orchestrating tissue damage control responses83, 
which contribute to disease tolerance to viral84 and helminthic85 infections as well during 
intestinal inflammation86. For example, ILC2 can sense alarmins, such as IL-33, and promote 
tissue damage control in epithelia, via a mechanism that involves the production of the EGF-
like factor amphiregulin83, 84, 86 (Figure 3b). Engagement of natural cytotoxicity receptors 
(NCRs) in ILC3 can sense ligands expressed by pathogens as well as self-ligands up-
regulated in response to cellular stress83, resulting in the production of IL-22, an IL-10 family 
member that promotes epithelia repair and regeneration87 (Figure 3b). 
Regulatory T cells (TREG). Natural loss of function mutations in the TREG cell lineage 
commitment transcription factor forkhead box P3 (Foxp3) are associated with development 
of severe immunopathology, in mice and in humans88. This suggests that TREG cells 
contribute to tissue damage control and presumably therefore regulate the establishment of 
disease tolerance to infection. The physiological functions assigned to TREG cells have long 
been related, almost exclusively, to their capacity to restrain adaptive and to a lesser extent 
innate immune responses88. More recently however, tissue-resident TREG cells were show to 
promote tissue damage control mechanisms89-91 that confer disease tolerance to Influenza 
virus infection90. This protective effect involves signaling through alarmins, such as IL-18 or 
IL-33, that elicit the production and secretion of amphiregulin15, 89, 90 by tissue-resident TREG 
cells89-91	(Figure 3c). Whether tissue-resident TREG cells protect parenchyma cells via direct 
interaction, or indirectly through immunoregulatory mechanisms involving tissue-resident 
macrophages or ILCs has not been established (Figure 3c). 
Stress and damage responses in immune cells. When exposed to different forms of 
infection-associated stress, tissue-resident macrophages, ILCs and TREG cells should 
activate the same stress and damage responses that operate in parenchyma cells to 
promote tissue damage control and disease tolerance to infection. For example, NRF2 
activation in macrophages36 and T cells92 exerts immunoregulatory effects that promote 
tissue damage control. Furthermore, HIF1α orchestrates a metabolic response in 
macrophages40, 93 and shifts the balance between TH17 and TREG cells94, modulating 
immune-driven resistance and possibly disease tolerance to infection. Activation of other 
stress and damage responses in tissue resident leukocytes is likely to exert similar effects, 
but this is yet to be determined experimentally. 
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PATHOGEN CLASS-SPECIFIC TISSUE DAMAGE CONTROL 
Multicellular organisms establish stable symbiotic interactions with a wide variety of 
microorganisms, which impact on different aspects of their physiology95, while modulating 
resistance as well as disease tolerance to pathogens (Box 3)22. Infection by viruses, 
bacteria, fungi, protozoan parasites or helminthes impose distinct forms of stress and 
damage to host parenchyma cells, driven by intrinsic differences in virulence mechanisms as 
well as by the countervailing host immune-driven resistance mechanisms elicited. Thus, 
tissue damage control mechanisms probably act in a pathogen-specific manner to confer 
disease tolerance to different types of infection, as demonstrated originally in flies96 and 
thereafter in mice6, 97, 98. In this section we discuss how immune-driven resistance to a 
different pathogen classes regulates tissue damage control mechanisms to establish 
disease tolerance to those classes of pathogens. 
 
Intracellular pathogens. Host resistance to intracellular pathogens, such as viruses and 
certain bacteria, relies to a large extent on cytotoxic mechanisms driven by type 1 immunity 
and the subsequent immune targeting of infected cells for programmed cell death99. Most 
immune-driven mechanisms killing intracellular pathogens fall under the control of the TH1 
signature cytokine IFNγ, which promotes tissue damage through various mechanisms, 
including i) macrophage polarization towards an anti-microbial response associated with the 
production of ROS and RNS, ii) activation of CD8+ cytotoxic T (TC) cells and NK cells to kill 
infected cells via the perforin/granzyme B-dependent lytic pathway or via the ligation of 
surface death receptors and iii) B cell activation towards the production of cytolytic 
antibodies, targeting infected cells for complement and Fc receptor mediated cellular 
cytotoxicity (Figure 4a). Tissue damage control mechanisms countering type 1 
immunopathology should not therefore rely on cytoprotection of infected cells, as this would 
compromise resistance to intracellular pathogens. Instead these tissue damage control 
mechanisms promote cell regeneration and tissue repair as the means to compensate for 
loss of parenchyma cells and to restore tissue homeostasis15, 90 (Figure 4a). The 
mechanisms via which this occurs are not fully established but are likely to be tissue 
specific6 and to involve the production of epidermal growth factors (EGF) and platelet 
derived growth factor (PDGF) family members as well as cytokines such as transforming 
growth factor (TGF)-β, which promote stem cell proliferation and/or differentiation into 
parenchyma cells and thereby restore tissue integrity and function23 (Figure 4a). 
Extracellular parasites. Resistance against extracellular metazoan parasites relies to a 
large extent on type 2 immunity99	 100. Some of these parasites are damaging to host 
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parenchyma tissues, presumably explaining why type 2 immunity promotes the activation of 
tissue damage control mechanisms that confer disease tolerance to infection101	(Figure 4b). 
Type 2 immunity targets pathogens primarily for containment or expulsion, likely based on 
the inherent failure of immune-driven cytotoxic molecules to kill large metazoan parasites 
such as helminths (Figure 4b). In addition, type 2 cytokines promote macrophage 
polarization towards granuloma formation, containing pathogens and depriving them from 
essential nutrients. This resistance mechanism, known as nutritional immunity [G], is 
perhaps best illustrated by the modulation of host iron metabolism as a strategy to deprive 
pathogens from this essential nutrient102. However, macrophage polarization by type 2 
cytokines also deprives pathogen access to other essential nutrients such as arginine, 
depleted by arginase expression in macrophages103. Moreover, arginine depletion also 
controls sustained T cell activation and as such limits immunopathology103. As a trade-off, 
nutritional immunity can impose metabolic stress to host parenchyma cells, activating stress 
responses that confer metabolic adaption and possibly tissue damage control and disease 
tolerance to extracellular parasites (Figure 4b).  
Extracellular bacteria and fungi. Resistance to infections by extracellular bacteria and 
fungi relies to a large extent on TH17 immunity99. Most of the resistance mechanisms 
associated with TH17 immunity, including pathogen killing, are mediated via the recruitment 
and activation of neutrophils99. This is often associated with the development of 
immunopathology, as illustrated at epithelial barriers, where ROS and elastase produced by 
neutrophils can cause epithelial cell damage and compromise disease tolerance to 
pathogenic Gram-negative bacteria such as Burkholderia pseudomallei104	 (Figure 4c). TH17 
immunopathology is counteracted by tissue damage control mechanisms that protect 
epithelial barriers against oxidative stress and damage as well by additional mechanisms 
promoting tissue repair and regeneration (Figure 4c). Some of these are regulated directly or 
indirectly by IL-22, produced by TH17 or by ILC3 cells and signaling via the IL22R expressed 
by epithelial cells84, 86, 105. Other cytokines produced by TH17 cells, including IL-17, can 
amplify this protective response, synergizing with fibroblast growth factor (FGF) 2 produced 
by TREG cells to promote tissue damage control at epithelial barriers106	(Figure 4c).	 
 
DISEASE TOLERANCE TO CO-INFECTIONS 
Pathogen class-specific tissue damage control mechanisms are particularly relevant in the 
context of co-infections, as illustrated for bacterial pneumonia following influenza virus 
infection107. This is probably also the case for co-infections by rhinovirus, adenovirus or 
parainfluenza and Streptococcus pneumoniae as well as for Haemophilus influenza and 
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Moraxella catarrhalis co-infections107. Several mechanisms may contribute to worsen the 
clinical outcome of these co-infections in that viral infections can compromise immune-driven 
resistance97 or tissue damage control15 mechanisms against bacterial co-infections, as 
illustrated for influenza virus and Legionella pneumophila co-infections97 15. The mechanisms 
via which viruses compromises disease tolerance to secondary bacterial infections are 
probably multi factorial and have been associated with deregulated production of EGF-like 
factors, such as amphiregulin15, presumably by lung-resident ILCs84 and TREG90.	
Immune-driven resistance mechanisms targeting viruses can also promote, rather than 
impair, disease tolerance to bacterial infections. For example, regulation of IL-1β-induced 
inflammation by type I IFN prevents the lethality of systemic Streptococcus pyogenes 
infection, without affecting bacterial load108. In this case, signaling via type I IFN receptor in 
macrophages, DCs and neutrophils represses IL-1β transcription, through signal transducer 
and activator of transcription STAT1, and to a lesser extent STAT2, ultimately preventing the 
development of lethal IL-1β-driven inflammation108.	
Disease tolerance against one class of pathogens has also been shown to antagonize 
immune-driven resistance against other pathogen-classes. For example, the induction of 
HO-1 expression promotes disease tolerance to the blood stage of Plasmodium infection12, 
20, 21, 30 but impairs resistance to Salmonella enterica subsp.	enterica serovar Typhimurium 
co-infection98. This is thought to involve deregulated heme-driven mobilization of 
granulocytes from the bone marrow during Plasmodium infection with concomitant induction 
of HO-1, reducing subsequent capacity of myeloid cells to generate ROS in response to S. 
Typhimurium98. Of note, genetic confirmation of this mechanism requires further 
investigation.  
 
PHARMACOLOGICAL MODULATION OF DISEASE TOLERANCE 
In some cases, effective pathogen elimination by immune-driven resistance mechanisms 
fails to overcome the morbidity or mortality associated with infection. Moreover, current anti-
microbial approaches also often fail to treat infectious diseases. In these cases, a rational 
pharmacological targeting of stress and damage responses controlling tissue damage 
control may act therapeutically through the establishment of disease tolerance to infection, 
as illustrated for pharmacological targeting of adenosine receptors109 or labile heme16, which 
establish disease tolerance to sepsis16, 109 or malaria20, 21, 30 in mice.  
Several pharmacological strategies can be envisioned when targeting labile heme, as it 
accumulates in plasma during bloodstream infections. In some instances, administration of 
hemopexin, a plasma protein that binds avidly to labile heme and neutralizes its deleterious 
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effects, confers tissue damage control and disease tolerance to sepsis in mice16. The 
pathological effects of labile heme can also be neutralized by gasotransmitters such as CO21 
or NO29, which bind avidly to ferrous heme-iron (Fe2+) in hemoproteins. In the case of CO, 
this gasotransmitter blocks heme-iron oxidation (Fe2+->Fe3+) and inhibits heme release from 
hemoproteins, preventing its accumulation in plasma during bloodstream infections20, 21. 
Remarkably, this is sufficient to confer protection against lethal forms of severe malaria in 
mice20, 21, 30. When used pharmacologically, NO also suppresses the pathogenesis of severe 
forms of malaria in mice, but this occurs via an indirect mechanism involving the activation of 
the transcription factor NRF2, the induction of HO-1 expression and the downstream 
generation of CO, which consequently establishes disease tolerance to malaria30, 31. In 
addition from preventing heme release from extracellular hemoglobin, CO exerts 
cytoprotective effects110 that are likely to promote tissue damage control and disease 
tolerance to infection. Labile heme is a potent pro-oxidant and as such pharmacologic use of 
anti-oxidants such as N-acetyl cysteine are efficient in preventing its pathogenic effects, 
conferring tissue damage control and disease tolerance to malaria12, 13. Moreover, 
downstream events in the signaling transduction pathways driving heme cytotoxicity, e.g. 
sustained activation of c-Jun N-terminal kinases, can also be targeted pharmacologically to 
promote recovery and survival through tissue damage control during malaria infection13. 
Pharmacological targeting of metabolic stress responses such as the one regulated by 
AMPK, confers protection against the development of organ dysfunction associated with the 
pathogenesis of sepsis in mice111. This is not associated with overt modulation of the host 
pathogen load, suggesting that AMPK activation contributes to the establishment of disease 
tolerance to sepsis111. In further support of this notion, pharmacological AMPK activation in 
the brain is sufficient per se to confer protection against polymicrobial infections in mice112. 
Another possible approach consists in targeting the inflammatory response to infection, 
without interfering with immune-driven resistant mechanisms. This can be achieved, for 
example via pharmacologic inhibition of topoisomerase 1 (Top1), suppressing the 
recruitment of RNA polymerase II (RNAPII) to the promoter of PRR-responsive genes113. 
This approach confers a net survival advantage against viral and bacterial infections as well 
as against sterile tissue injury in mice113, presumably through the establishment of disease 
tolerance. Pharmacologic use of cytokines that act in protective manner on parenchyma 
tissues, such as IL-10114, IL-22115 or EGF-like factors, such as amphiregulin15, were also 
used promote disease tolerance to infections in mice. 
It is also possible to target pharmacologically specific resistance mechanisms associated 
with the development of immunopathology, as a therapeutic approach to disease tolerance 
to infection116. As a trade-off however, this strategy can be associated with reduced 
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resistance and hence increased pathogen load, as illustrated for influenza A virus117 and 
Trypanosoma cruzi118, as well as for human rhinoviruses119 infections in mice. In some 
cases, however, this does not appear to be the case, as illustrated for the therapeutic effect 
exerted by the cyclooxygenase inhibitor ibuprofen against Mycobacterium tuberculosis 
infection in mice116.  These, among other studies, provide the proof-of-principle that 
immunoregulatory mechanisms can be targeted pharmacologically to confer tissue damage 
control and disease tolerance to different types of infection where anti-microbial therapy 
alone fails to overcome host morbidity or mortality. 
Perhaps an important issue is how to develop therapeutic approaches, which might target 
or even identify tissue damage control mechanisms conferring disease tolerance to infection. 
Functional “drug screens” are one possible way forward, an approach that proved successful 
in identifying the ATM kinase as a molecular target via which the anthracycline [G] family of 
chemotherapeutic agents induce disease tolerance to sepsis in mice17. Namely, when 
administered at relatively low concentrations to infected mice, epirubicin, doxorubicin or 
daunorubicin are protective against the development of sepsis17. This therapeutic effect is 
associated with the induction of tissue damage control and is dissociated from the host 
pathogen load17. As the protective effect mediated by anthracyclines requires activation of 
the ATM kinase17, this indicates that targeting DNA damage responses could have potential 
therapeutic potential in the establishment of disease tolerance to sepsis. 
Finally, a number of antibiotics are labeled as “immunomodulatory” based on their ability 
to improve the outcome of chronic disorders via mechanisms not readily explained on the 
basis of their anti-microbial activity. These fall into at least four families, namely, macrolides, 
fluoroquinolones, tetracyclines and polymyxines, of which macrolides have the best 
documented activity120. For example, the therapeutic effects of the macrolide azithromycin in 
chronic inflammatory pulmonary diseases including cystic fibrosis, can be dissociated from 
its antibacterial activity120. The “immunomodulatory” effect of these antibiotics is likely to go 
beyond inhibition of pro-inflammatory mediators and other immune processes and could 
involve the modulation of molecular pathways associated with lifespan regulation. In support 
of this notion, tetracyclines increase longevity in C. elegans via a mechanism involving the 
UPR121, a damage response, which as discussed above promotes disease tolerance to 
infections. Colistin induces the activation of the FOXO pathway, another lifespan extension 
pathway in C. elegans that confers disease tolerance to Gram-negative infection122. Of note, 
these antibiotics have not been shown to exert a direct effect on tissue damage control 
mechanisms and more definitive conclusions await experimental validation, for example 
using germ-free organisms. 
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CONCLUDING REMARKS AND PERSPECTIVES 
It is now clear that multicellular organisms use two genetically distinct defense strategies to 
limit the pathogenicity of microbes. The prevailing view has long been that immune-driven 
resistance mechanisms that contain, kill or expel invading microbes are the prevailing 
defense strategy against infectious diseases. However, disease tolerance is an equally 
important host defense strategy against infection, which does not exert a direct negative 
impact on pathogens, while interacting functionally with immune-driven resistance 
mechanisms to limit the severity of infectious diseases. The cellular and molecular bases of 
these interactions are only now starting to be appreciated. A series of experimental 
approaches have been used to identify and characterize the molecular and cellular basis of 
tissue damage control mechanisms conferring disease tolerance to a variety of pathogens. 
These have so far been related restricted to number of evolutionarily conserved stress and 
damage responses, in some cases associated with immunoregulatory responses controlling 
resistance mechanisms. How immunoregulatory mechanisms modulate these stress and 
damage responses to confer disease tolerance to infection remains largely unexplored. 
There is also a growing body of experimental evidence to suggest that symbiotic microbes 
can regulate disease tolerance as the means to prevent their pathogenicity as well as that of 
other pathogens. Whether this occurs via the induction of immunoregulatory mechanisms 
and/or the activation of stress and damage responses remains however, to be established. 
Deciphering the cellular and molecular nature of these interactions should be instrumental to 
understand and perhaps subsequently shape therapeutic strategies to manipulate protection 
against major infectious diseases where resistance mechanism fail to limit disease severity. 
Such approaches are also likely to be transformative towards overcoming the growing global 
health threat imposed by the emergence of multidrug resistance in pathogens as well as to 
treat co-infections associated with high levels of morbidity and mortality. 
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Box 1: TOLERANCE AND DISEASE TOLERANCE. 
While there is a growing interest in understanding disease tolerance, both at a mechanistic 
level as well as in its potential therapeutic application, the concept and associated 
terminology are often misused. This is likely due to the fact that tolerance is broadly used to 
define some core properties of the immune system. These include immunological tolerance, 
which refers to an active process via which specific antigens become non-immunogenic, that 
is, fail to trigger adaptive immunity in a given individual123, based on immunoregulatory 
mechanisms that eliminate or suppress the activation and proliferation of antigen-specific B 
and T cells. Immunological tolerance provides an explanation for immune self-non-self 
discrimination, a concept deeply rooted in the understanding of immunity. While some of the 
mechanisms regulating immunological tolerance and disease tolerance are functionally 
related these are clearly distinct phenomena. 
Tolerance is also used to refer to another related phenomenon in which innate immune 
cells, particularly macrophages, modulate responses to bacterial lipopolysaccharide (LPS). 
The cellular and molecular bases for LPS tolerance have been extensively studied and 
relate primarily to the induction of epigenetic modifications in enhancers, which modulate 
gene transcription in response to TLR4 signaling124. This is not specific to TLR4, occurring 
downstream of other PRRs125 and other sensors18. In some instances this response, coined 
as “trained immunity”126, has been functionally linked to the induction of disease tolerance18.  
Tolerance also refers to a related phenomenon in which exposure to a sub-lethal dose of 
a given agonist renders cells, tissues, organs or organisms refractory to a subsequent 
dosage of the same substance that would otherwise be deleterious. This adaptive response, 
also referred to as hormesis or accomodation relies on the activation of a number of 
evolutionarily conserved genetic programs that confer protection against stress and damage 
induced by these agonists. Some of these genetic programs overlap with those conferring 
tissue damage control and disease tolerance to infections1, 3. 
We use the term disease tolerance to refer explicitly to the same concept defined over a 
century ago in the plant literature5, 6, in which disease tolerance defines a defense 
mechanism that limits “damage to functions and structures”8 imposed upon the host during 
an infection, without interfering with pathogen load5, 6 (Box 1). Of note, while disease 
tolerance is not, by definition, associated with modulation of pathogen load, one cannot 
exclude its impact on pathogen physiology, not revealed by corresponding changes in 
pathogen load. 
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Box 2: IDENTIFYING MECHANISMS CONTROLLING DISEASE TOLERANCE EXPERIMENTALLY 
By definition, genetic control of disease tolerance should reveal itself by variations of disease 
severity without a direct correlation with pathogen load. However, while the genetic 
programs underlying the stress and damage responses regulating tissue damage control 
and disease tolerance to infection should not exert direct effects on pathogens, this is often 
difficult to reveal because of the inter-relationship between tissue damage control and 
immune-driven resistance mechanisms. For example, when operating in parenchyma cells, 
genes regulating tissue damage control mechanisms should allow for immune-driven 
resistance mechanisms to operate in a more robust and effective manner without the onset 
of immunopathology. As such tissue damage control mechanisms can act indirectly to exert 
a negative impact on pathogens. It follows that to dissociate disease tolerance from 
resistance to infection often requires that resistance be stably maintained, e.g. through the 
use of anti-microbial agents. Under such conditions, modulation of host protection from 
infection is likely to involve tissue damage control mechanisms that contribute to the 
establishment of disease tolerance. Most studies dealing with mechanisms of host protection 
against infection are not designed under the conceptual framework of disease tolerance and 
as such it is often difficult to disentangle whether host protection relies on disease tolerance 
versus resistance to infection. 
When designing experimental approaches aimed at identifying mechanisms regulating 
disease tolerance one should consider the quantification of physiologic parameters reporting 
on host homeostasis, such as temperature, O2, pH, osmolarity or glucose concentrations. 
These physiologic parameters however, report only indirectly on disruption of host 
homeostasis. This can be overcome when quantifying parameters reporting more directly on 
organ, e.g. brain, cardiovascular, lung, kidney or liver, function. When reported to host 
pathogen load these parameters can be used to reveal variations in disease tolerance. Of 
note, these parameters should also be quantified at steady state, i.e. before infection, 
defining host “vigor”. When the quantification of these parameters is not possible, incidence 
of mortality can be used to reveal an irreversible breakdown of homeostasis13, 16, 17, 20.  
Host pathogen load should be quantified, ideally throughout the course of an infection, for 
example by sampling tissues where pathogens accumulate, e.g. blood in malaria, lung in 
pneumonia, liver in hepatitis, etc. A potential bias of this approach is that changes in 
pathogen behavior, such as reflected by variations in tissue tropism and accumulation are 
not account for. An alternative approach is to quantify pathogen load in “whole body”, as 
performed routinely in flies5, 9, 10, 127. This is more challenging in other species, including 
rodents, but can be achieved, for example, using transgenic pathogens expressing reporter 
probes quantified throughout the course of an infection by whole body imaging29.  
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The approaches used to reveal disease tolerance, are most often inferred form a host 
health reaction norm (i.e. pattern of phenotypes produced by a given genotype under 
different environmental conditions) to pathogen burden5, 128. Variations in reaction norms, 
associated with changes in the slopes of their linear regressions, are also used to reveal 
genetic variations in disease tolerance5, 11, 128, 129. In this reaction norm analysis, each 
individual (genotype) is represented according to a single health parameter and pathogen 
load value, i.e. ratio of minimum health parameter to maximum pathogen load5, 11, 128, 129. As 
these reaction norms do not provide information on how the relation between health and 
pathogen load vary over time128. An alternative approach consists in plotting health 
parameters versus pathogen load over time130. The resulting health curves allow to follow 
“disease trajectories”, revealed by the concomitant changes in health and pathogen load 
over time32, 130. Under some assumptions the data from these health curves can be used to 
estimate individual variations in disease tolerance32, 130. 
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Box 3. MICROBIOTA AND DISEASE TOLERANCE: There are numerous examples of symbiotic 
microorganisms that enhance resistance to infection in animals. The bacterial endosymbiont, 
Wolbachia, for example, enhances resistance to Drosophila C virus in flies10, 131 and to 
dengue and chikungunya virus infections in mosquitoes132 (Figure 5). Symbiotic interactions 
between bacteria and mice can also promote immune-driven resistance mechanisms against 
viral133, bacterial134 or protozoan135, 136 infections (Figure 5). This argues that the 
establishment of stable symbiotic interactions between microcellular and multicellular 
organisms is a widespread recurrent trait that modulates host resistance against a variety of 
pathogens (Figure 5). Symbiotic bacteria can also modulate tissue damage control and 
disease tolerance to infection in multicellular organisms (Figure 5)22, 137. This is again 
illustrated by Wolbachia, which enhances disease tolerance to flock house virus infection in 
flies10. In mice, bacteria that colonize gut, such as the human symbiont Bacteroides fragilis, 
also confer disease tolerance to Helicobacter hepaticus infection138 while the gut E. coli 
O21:H+ symbiont confers disease tolerance to Burkholderia thailadensis or S. Typhimurium 
infections137. Though the mechanisms via which endosymbiotic bacteria promote disease 
tolerance to virus infection in insects are not clearly established, some mechanistic insight is 
emerging from observations of similar beneficial host-microbe interactions in mice22. For 
example, the gut commensal E. coli O21:H+ confers disease tolerance to systemic bacterial 
infections via a mechanism that involves the activation of the NLRC4 inflammasome, which 
induces the production of IL-18137. This alarmin sustains the production of insulin-like growth 
factor-1 (IGF-1), which prevents the development of muscle atrophy through the activation of 
phosphoinositide 3-kinase (PI3K)/Akt signal and the repression of the expression of the E3 
ubiquitin ligases Atrogin-1 and Murf1 in muscle cells137. This confers protection against 
muscle and weight loss, a common pathological outcome of infection. Other mechanisms via 
which components of the microbiota modulate disease tolerance involve the expression of 
fucosylated proteins in the gut epithelia lumen, which modulate microbiota composition, 
metabolism and gene expression in a manner that promotes disease tolerance to enteric 
infection by Citrobacter rodentium139. Modulation of host metabolism by bacterial 
components of the microbiota140 is also likely to modulate tissue damage control 
mechanisms and disease tolerance to infection22. 
In the same way that pathogens can modulate resistance mechanisms, some also 
promote	disease tolerance as the means to support their own survival, proliferation and/or 
transmission. For example, S. Typhimurium induces the activation of host Rho GTPases and 
mitogen-activate protein kinases (MAPK), leading to NF-κB activation and to the expression 
of downstream pro-inflammatory genes in the gut epithelium. This allows S. typhimurium to 
overcome immune-driven colonization resistance imposed by resident gut microbiota 
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bacteria141, promoting gut epithelial cell invasion and systemic infection142. During epithelial 
invasion however, S. Typhimurium delivers, through type III secretion systems, the 
proteases PipA, GogA and GtgA, which target the NF-κB family members RelA and RelB 
and inhibit the expression of downstream pro-inflammatory genes143. This immunoregulatory 
effect limits tissue damage and disease severity without interfering with host pathogen 
load143, revealing that this action of S. Typhimurium promotes disease tolerance to infection. 
Other examples include the induction of IL-10 by Staphylococcus aureus through a 
mechanism involving the recognition of bacterial peptidoglycan via TLR2 and leading to the 
suppression of unfettered T cell activation, thus conferring tissue damage control and 
disease tolerance to Staphylococcus aureus infection144. 
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Figure Legends 
Figure 1: Tissue damage control and disease tolerance. Immunity exerts a negative 
impact (–|) on pathogens while triggering (à) stress and damage in host parenchyma 
tissues, possibly leading to cytotoxicity, tissue dysfunction and disease. Tissue damage 
control mechanisms involve a number of stress and damage responses that act in a 
concerted manner to protect parenchyma cells and tissues from damage emanating from 
pathogens or from immune-driven resistance mechanisms and leading to cytotoxicity, tissue 
dysfunction and disease. Tissue damage control mechanisms rely, initially, on stress 
responses that rewire metabolic pathways as the means to preserve the functional outputs 
of parenchyma cells1, 3, 145. If stress persists over time, damage to intracellular metabolites, 
macromolecules and cellular organelles develops1. This is countered by damage responses 
that repair these different types of damage as the means to preserve the functional outputs 
of parenchyma cells. If this second layer of tissue damage control fails to preserve the 
functional outputs of parenchyma cells, the default response becomes programmed cell 
death. When this occurs, the last layer of tissue damage control becomes cellular 
regeneration and tissue repair. If this still fails to preserve or restore the functional outputs of 
parenchyma tissues, the outcome is tissue dysfunction and damage, as reveled by the 
appearance of the clinical signs and symptoms of infectious diseases. Stress, damage and 
regenerative responses underlying tissue damage control are also regulated by immunity, in 
a manner that contributes to establish disease tolerance to infection. 
 
Figure 2: Relative contribution of stress and damage responses to the establishment 
of disease tolerance to infection. Pathogen-derived toxins, such as pore-forming toxins, 
can act as a major driving force in the pathogenesis of infectious disease146, via the induction 
of host cellular stress and damage, eventually leading to programmed cell death146. This 
argues that toxins can impair host disease tolerance to infection via metabolic deregulation 
of host cells, eventually leading to programmed cell death. Production ROS and RNS by 
macrophages or polymorphonuclear cells is a common resistance mechanism against a 
variety of pathogens147, 148. This however, can lead to oxidative stress147, 148, which is 
monitored and countered by the Kelch-like ECH-associated protein 1 (KEAP1)28, which 
under homeostatic conditions constitutively promotes the ubiquitination and proteolytic 
degradation of the transcription factor NRF227, 28. ROS or RNS repress KEAP1 and allow 
NRF2 activation, triggering the expression of effector genes regulating oxidative stress 
responses27, 28. Hypoxia is countered by a stress response triggered by the prolyl 
hydroxylase domain protein (PHD2)38. This O2 sensor constitutively represses the activity of 
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the HIF family of transcription factors that under normoxic conditions38. Under hypoxia, 
PHD2 activity is inhibited and HIFs are activated, orchestrating the stress response to 
hypoxia38. While usually associated exclusively with hypoxia, HIF activation also occurs in 
response to i) PRR signaling, ii) reduced intracellular iron availability or iii) inhibition of 
mitochondria cytochrome c oxidase leading to the production of ROS. Therefore HIF 
activation might confer metabolic adaptation to different types of stress associated with 
infection38. Metabolic stress, such as resulting for example from variations in intracellular 
ATP concentration are associated with AMP generation by adenylate kinase. This is sensed 
by the AMP-activated protein kinase (AMPK)149, which triggers a metabolic stress 
response149, 150 likely contributing to the establishment of disease tolerance to infection111	112. 
Other forms of metabolic stress, such as for example resulting from variations in systemic 
glucose levels are sensed indirectly through blood insulin levels by the insulin receptor. This 
activates constitutively a signal transduction pathway involving phosphoinositide 3-kinase 
(PI3K) and protein kinase B (AKT) and repressing the forkhead box O (FOXO) family of 
transcription factors151. When insulin levels drop PI3K and AKT activation are reduced, 
promoting the activation of the FOXO family of transcription factors151. FOXO activation 
orchestrates a metabolic response that allows essential cellular functional outputs to be 
maintained under sub-optimal glucose supply151. FOXO activation in epithelial cells regulates 
the expression of anti-oxidant152 and antimicrobial genes153 that contribute to maintain 
epithelial barrier integrity, acting in a protective manner against infection in flies152, 153 and 
mice153, 154. However, activation of FOXO1 and FOXO3α in muscle cells, promotes myofiber 
atrophy and muscle wasting associated with sepsis in mice155 and Mycobacterium marinum 
infection in flies127. This suggests that FOXO family members act in a tissue-specific manner 
to promote or repress disease tolerance to infection. Osmotic stress is sensed by the A-
kinase anchor protein 13 (AKAP13), which activates NFAT544, a transcription factor that 
provides metabolic adaptation to osmotic stress and tissue damage control to infection. 
Osmotic stress is also sensed by inflammasomes156, containing the NLRP3 or the CARD 
domain-containing protein 4 (NLRC4)157. Metabolite damage imposed by structural 
modifications that promote the formation of crystals, acts in a proinflammatory manner as 
illustrated, for example, for uric acid-driven monosodium urate crystals158 or cholesterol 
crystals159. These are sensed by NLRP3 inflammasomes, triggering a downstream signaling 
transduction pathway, which involves the apoptosis-associated speck-like protein containing 
a CARD (ASC), caspase-1 and IL-1849. Extracellular release of metabolites, such as for 
example ATP, is sensed by the purinergic P2 receptor P2X ATP-gated ion channel160, which 
signals via inflammasomes156 to promote inflammation and tissue damage160. Catabolism of 
extracellular ATP/ADP into AMP and subsequently into adenosine, by the nucleoside 
triphosphate dephosphorylase CD39 and the ecto-5'-nucleotidase CD73, respectively160, 
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exerts immunoregulatory effects, promoting the establishment of disease tolerance 
Toxoplasma gondii161 or Helicobacter162 infections in mice. Presumably these effects are 
mediated via adenosine-driven signaling through transmembrane adenosine G protein-
coupled cell surface receptors109, 163. Lipid peroxidation is countered by several damage 
responses50 that induce HO-131, a heme catabolizing enzyme that degrades the lipophilic 
pro-oxidant heme into biliverdin, which is converted by biliverdin reductase into the lipophilic 
anti-oxidant bilirubin164 and promotes disease tolerance to bloodstream infections16, 20, 21, 29-31. 
Whether activation of the glutathione/GPX4 pathway promotes disease tolerance to infection 
has not been established. Proteoxic damage is sensed in the cytoplasm by chaperones 
from the heat shock protein (HSP) family, which activate the transcription factor heat shock 
factor 1 (HSF1)54 and is sensed in the endoplasmic reticulum by the binding immunoglobulin 
protein (BiP)/78 kDa glucose-regulated protein (GRP-78) chaperone and the inositol 
requiring protein-1 (IRE1)53, which activate the unfolded protein response (UPR). HSF1 
activation confers a survival advantage against Enterococcus faecalis and P. aeruginosa 
infections in Caenorhabditis elegans55, 56 as well as against Listeria monocytogenes infection 
in mice57, where it contributes only marginally to pathogen clearance57. Activation of the 
UPR, via the X-box binding protein 1 (XBP1), prevents immunopathology associated with P. 
aeruginosa infection in C. elegans58 while preserving homeostatic control of microbiota 
interactions with host gut epithelia53. The DNA damage responses orchestrated by ATM17 
and by p53165 confer tissue damage control and disease tolerance to pulmonary bacterial 
infections in mice. Damage to cellular organelles in countered by the autophagy response. 
Damage to cellular organelles is countered by autophagy, which relies on a cellular 
vesicular system initiated by a process of nucleation of damaged organelles62. Autophagy 
modulates disease tolerance to a variety of infections63 64	17. 
 
Figure 3: Immune regulation of tissue damage control. a) Tissue resident 
macrophages use PRR or other sensors such as interleukin receptors or AhR to sense 
environmental cues that alert for disruption of homeostasis, such as pathogens (green 
circles), dying infected cells, alarmins, e.g. DAMPs IL-1, IL-18, IL-33 or L-kynurenine 
generated by host parenchyma cells via the tryptophan 2,3-dioxygenase, respectively. 
Signaling via these sensors, polarizes macrophage responses to assist parenchyma cells in 
restoring homeostasis18, 166, 167. This non cell-autonomous mechanism supporting tissue 
damage control and disease tolerance to infection is mediated via the secretion of cytokines, 
e.g. tumor necrosis factor (TNF), IL-6, IL-10, as well as growth factors, e.g. transforming 
growth factor beta (TGF-β) and PDGF family members, among others. b) Tissue resident 
ILCs can also sense alarmins, e.g. IL-33, IL-1, via the corresponding IL receptors (ILR) or 
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sense cellular stress and damage via natural cytotoxicity receptors (NCR)83. These trigger 
the production of cytokines, e.g. IL-22, and EGF family members, e.g. amphiregulin (AREG), 
which promote tissue damage control in parenchyma cells, e.g. epithelial cells83, 84, 86. c) 
Tissue-resident TREG also sense alarmins, e.g. IL-18 and IL-33, which elicit the production 
of EGFs, i.e. amphiregulin89-91, acting on parenchyma cells to promote tissue damage 
control89-91 and confer disease tolerance to infection90. 
 
Figure 4: Pathogen class-specific tissue damage control mechanisms. a) Type 1 
immunity drives resistance to viruses and intracellular bacteria (green circles), such as 
Listeria monocytogenes, Salmonella spp. and Mycobacteria spp., as well as against 
intracellular protozoan parasites such as Leishmania spp.99. Tissue damage control 
mechanisms countering type 1 immunopathology rely on cellular regeneration and tissue 
repair to restore homeostasis15, 90. The mechanisms via which type 1 immunity contribute to 
this tissue damage control response are not clear but are likely to involve the production of 
EGFs, TGF-β and PDGF. These can drive the proliferation and differentiation of stem cells 
into functional parenchyma cells, restoring tissue integrity and function23. b) Resistance to 
extracellular metazoan parasites and other large parasites is mediated and/or involves type 
2 immunity99, 100. Pathogen neutralization is achieved via different mechanisms orchestrated 
by TH2 signature cytokines, e.g. IL-4, IL-5 and IL-13, as well as by additional type 2 
cytokines such as thymic stromal lymphopoietin (TSLP), IL-25 or IL-33, secreted by 
damaged cells99	100. TH2 signature cytokines drive B cell activation towards the production of 
high affinity pathogen-specific IgG1 and IgE antibodies that act via Fc-dependent 
mechanisms to trigger the activation of eosinophils, mast cells and basophils, expelling 
pathogens across epithelia100. Some of these parasites, e.g. helminthes, are damaging to 
parenchyma cells and a such type 2 immunity encompasses tissue damage control 
mechanisms that confer disease tolerance to infection by these parasites101. These 
mechanisms involve the production of EGF, VEGF, TGF-β and resistin-like molecule α and β 
(RELMα/β). c) TH17 immunity confers resistance to extracellular bacteria such as Klebsiella 
pneumoniae, Escherichia coli, Citrobacter rodentium, Bordetella pertussis, Porphyromonas 
gingivalis, and Streptococcus pneumoniae, and also to fungi such as Candida albicans, 
Coccidioides posadasii, Histoplasma capsulatum and Blastomyces dermatitidis99. Activation 
of TH17 cells by cognate T cell receptor (TCR)/major histocompatibility complex (MHC) class 
II interaction and activation of ILC3 via engagement of IL1 receptor (IL-1R) by IL-1β secreted 
from damaged cells lead to the recruitment and activation of neutrophils104. TH17 
immunopathology is driven to a large extent by products of neutrophil activation, such as 
reactive oxygen species (ROS) and elastase. This is countered by tissue damage control 
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mechanisms regulated directly or indirectly by IL-22, originating from TH17, TH22 cells (not 
shown) or ILC3, and promoting tissue damage control. 
 
Figure 5. a) Symbiotic bacteria can promote resistance to infection in multicellular 
organisms22. Examples include the bacterial endosymbiont Wolbachia, which enhances 
resistance to Drosophila C virus infection in flies10, 131 and to dengue or chikungunya virus 
infections in mosquitoes132, 168. This protective effect has been linked to priming of the 
mosquito innate immune system	 and possibly competition for resources supporting 
pathogen replication. Symbiotic neomycin-sensitive bacteria can promote immune-driven 
resistance mechanisms against influenza A virus infection in mice, via mechanism involving 
bacterial sensing by inflammasomes133. The gut E. coli O86B7 commensal elicits an IgM 
antibody response directed against the galα(1,3)gal glycan that confers resistance to 
Plasmodium infection in mice and possibly in humans135 while Lactobacillus and 
Bifidobacterium confer resistance to Plasmodium infection in mice via a mechanism that has 
not been clearly established136. Other gram-negative bacterial components of the mouse gut 
microbiota are sensed by TLR4 and trigger an antigen-specific IgG antibody responses 
directed against Murein lipoprotein, which confer resistance to systemic E. coli infection134. 
b) Symbiotic bacteria can also promote disease tolerance to infection in multicellular 
organisms. For example, Wolbachia enhances disease tolerance to flock house virus 
infection in flies10 and against Plasmodium relictum infection in mosquitoes169. Symbiotic 
Bacteroides fragilis induces disease tolerance to Helicobacter hepaticus infection in mice via 
a mechanism that involves the expression of polysaccharide A. This capsular glycan is 
sensed by the host and induces IL-10 expression138, which acts on host parenchyma cells to 
promote tissue damage control and disease tolerance to Helicobacter hepaticus infection138. 
Bacterial symbionts such Clostridium strains170 also promote the development of TREG cells 
in mice, but whether these symbiotic consortia modulate disease tolerance to infections has 
not been established. The gut symbiont E. coli O21:H+ confers disease tolerance to systemic 
bacterial infections137 while unidentified bacterial microbiota modulate disease tolerance to 
enteric infection by Citrobacter rodentium139.  
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GLOSSARY  
Homeostasis: Maintenance of a stable physiologic “internal” state in multicellular organisms 
via feedback mechanisms that allow physiologic functions to proceed despite variations in 
the “external” environment.  
Immunopathology: Refers to a breakdown of homeostasis in which immunity acts as the 
main cause of disease. 
Necroptosis: A specific form of programmed cell death mediated via a genetically encoded  
mechanism involving the receptor-interacting serine/threonine-protein kinases 1 and 3 
(RIPK1/3) and the mixed lineage kinase domain-like (MLKL) pseudokinase. 
Ferroptosis: Genetically encoded form of programmed cell death driven by loss of activity of 
the lipid repair enzyme glutathione peroxidase 4 (GPX4) and the accumulation of lipid 
hydroperoxides. 
Nutritional immunity: An evolutionary conserved resistance mechanisms against infection 
based on the host's ability to withhold nutrients, such as iron, from pathogens. 
Alarmins: Endogenous molecules released from damaged cells and sensed by receptors of 
the immune system that alert for tissue dysfunction or damage, associated with disruption of 
homeostasis. 
Anthracycline: A class of red aromatic polyketides drugs derived from Streptomyces 
bacteria that intercalate into DNA, arresting transcription and cell division, a property widely 
used therapeutically against cancers. 
Stress: Any variations in the “external” environment that disrupts the maintenance of a 
stable physiologic environment where biologic processes are allowed to proceed. 
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